Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

Nivolumab OS Benefit Sustained in Long-Term Follow-Up for SCCHN

April 17th 2018

Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

Crizotinib Confirmed as Standard of Care for ALK+ Inflammatory Myofibroblastic Tumors

April 16th 2018

Treatment with crizotinib elicited an objective response rate of 50% for patients with ALK-positive advanced, inoperable inflammatory myofibroblastic tumor.

Abemaciclib Data Reviewed as New Breast Cancer Indications Added

March 12th 2018

Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.

PARP Inhibitors Arrive for BRCA+ Breast Cancer

March 11th 2018

The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.

Olaparib Breast Cancer Efficacy Highlighted in Added Analyses

March 8th 2018

Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma

February 21st 2018

The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.

FDA Grants Priority Review to Ivosidenib for IDH1+ AML

February 15th 2018

The FDA has granted a priority review designation to ivosidenib (AG-120) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration

February 15th 2018

Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.

FDA Approves Abiraterone for High-Risk Prostate Cancer

February 8th 2018

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.

Atezolizumab Combo Improves PFS by 3.5 Months in mRCC

February 6th 2018

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC

February 6th 2018

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

Celgene Acquiring Juno Therapeutics for $9 Billion

January 22nd 2018

Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.

FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma

January 22nd 2018

The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Nab-Paclitaxel/Gemcitabine Effective for Locally Advanced Pancreatic Cancer

January 20th 2018

Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.

Cabozantinib Improves OS, PFS in Advanced HCC

January 17th 2018

Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.

FDA Approves Arsenic Trioxide for Promyelocytic Leukemia

January 16th 2018

The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.

FDA Expands Afatinib's Approval for Lung Cancer

January 14th 2018

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

FDA Grants Priority Review to Novel Iobenguane I-131 Agent for Rare Neuroendocrine Tumors

December 29th 2017

The FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 for patients with malignant or recurrent pheochromocytoma or paraganglioma.

FDA Approval Sought for Ivosidenib in IDH1+ AML

December 26th 2017

A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.

Rituximab/Lenalidomide Regimen Misses Endpoint in Phase III Follicular Lymphoma Study

December 22nd 2017

The combination of rituximab and lenalidomide followed by maintenance therapy with the same regimen did not improve response nor progression-free survival compared with rituximab and chemotherapy with rituximab maintenance for patients with previously untreated follicular lymphoma.